Shares of Figure Technology (FIGR) have gained 0.2% over the past four weeks to close the last trading session at $37.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.11 indicates a potential upside of 31.7%.The mean estimate comprises nine short-term price targets with a standard deviation of $6.17. While the lowest estimate of $40.00 indicates a 7.3% increase from the c ...

Core Viewpoint - VAREX IMAGING (VREX) shares have increased by 3.2% recently, with analysts suggesting a potential upside of 29.9% based on a mean price target of $15.33 [1][11]. Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $3.06, indicating variability among analysts [2]. - The lowest estimate is $12.00, suggesting a 1.7% increase, while the highest estimate is $18.00, indicating a potential surge of 52.5% [2]. - Analysts' price targets can be misleading, as they may not accurately reflect the stock's future price movements [7][10]. Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding VREX's earnings prospects supports the expectation of an upside, as indicated by positive revisions in earnings estimates [4][11]. - The Zacks Consensus Estimate for the current year has risen by 1% over the past month, with one estimate increasing and no negative revisions [12]. - VREX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of VREX's potential gains, it does provide a useful guide for the direction of price movement [14].

Core Viewpoint - Daktronics (DAKT) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $23.67 indicating a 26.1% upside from the current price of $18.77 [1] Price Targets - The average price target consists of three estimates ranging from a low of $16.00 to a high of $31.00, with a standard deviation of $7.51, indicating variability among analysts [2] - The lowest estimate suggests a decline of 14.8%, while the highest indicates a potential upside of 65.2% [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about DAKT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank - DAKT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to potential biases and inflated targets set by analysts [3][8][10]

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has shown a 13% gain over the past four weeks, with a mean price target of $12.62 indicating a potential upside of 134.1% from the current price of $5.39 [1] Price Targets and Analyst Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $6.67, where the lowest estimate is $8.00 (48.4% increase) and the highest is $30.00 (456.6% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CMPX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, indicating a positive outlook [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]

Core Viewpoint - Braze, Inc. (BRZE) has shown a significant price increase of 23.8% over the past four weeks, with a mean price target of $46.63 indicating a potential upside of 33.5% from the current price of $34.93 [1]. Price Targets and Analyst Consensus - The average price target consists of 19 estimates ranging from a low of $38.00 to a high of $68.00, with a standard deviation of $6.53, suggesting a variability in analyst predictions [2]. - The lowest estimate indicates an 8.8% increase, while the highest suggests a 94.7% upside, highlighting the range of potential outcomes [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about BRZE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.2%, with one estimate moving higher and no negative revisions [12]. - BRZE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]. - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10].

Core Viewpoint - nCino (NCNO) shows potential for significant upside, with a mean price target of $34.8 indicating a 34.3% increase from the current price of $25.92 [1] Price Targets and Analyst Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $4.02, suggesting variability in analyst predictions [2] - The lowest estimate is $27.00, indicating a 4.2% increase, while the highest estimate is $41.00, suggesting a potential surge of 58.2% [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about nCino's earnings prospects, with a strong consensus on higher EPS estimates [11] - Over the last 30 days, five estimates have been revised upward, leading to a 55.1% increase in the Zacks Consensus Estimate [12] - nCino holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While consensus price targets may not be reliable indicators of the extent of potential gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Altimmune, Inc. (ALT) has shown a significant price increase of 28.4% over the past four weeks, with a mean price target of $17.88 indicating a potential upside of 229.3% from the current price of $5.43 [1] Price Targets and Analyst Consensus - The average price target for ALT includes eight short-term estimates ranging from a low of $1.00 to a high of $28.00, with a standard deviation of $8.81, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 81.6%, while the highest points to an upside of 415.7% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction, which can be a useful starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ALT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.8%, with one estimate moving higher and no negative revisions [12] - ALT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and consider them as one of many factors in their decision-making process [10]

Core Viewpoint - Evolv Technologies Holdings, Inc. (EVLV) shares have seen a 0.7% increase over the past four weeks, closing at $6.77, with a potential upside of 45.9% based on Wall Street analysts' mean price target of $9.88 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.25, indicating a consensus among analysts. The lowest estimate of $9.50 suggests a 40.3% increase, while the highest target of $10.00 indicates a 47.7% increase [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about EVLV's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 15% over the past month, with no negative revisions [11][12] - EVLV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, it should not be the sole basis for investment decisions due to the questionable reliability of analysts in setting these targets [3][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

McGraw Hill, Inc. (MH) closed the last trading session at $16.68, gaining 51% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.92 indicates a 25.4% upside potential.The average comprises 12 short-term price targets ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $2.71. While the lowest estimate indicates a decline of 4.1% from the current price lev ...

Core Viewpoint - Tetra Tech (TTEK) shows potential for further upside, with a mean price target of $42.4 indicating a 26.3% increase from its current price of $33.58 [1] Price Targets - The average price target consists of five estimates ranging from a low of $38.00 to a high of $48.00, with a standard deviation of $3.65, suggesting a consensus among analysts [2] - The lowest estimate indicates a 13.2% increase, while the highest suggests a 42.9% upside [2] - A low standard deviation indicates greater agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about TTEK's earnings prospects, as evidenced by upward revisions in EPS estimates, which correlate with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.4%, with one estimate increasing and no negative revisions [12] - TTEK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they often do not accurately predict stock price movements [7][10] - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [8]